Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy Fleischmann

Showing results (151-160 of 190) with videos related to

Pageof 19
Sort By:
Lancet (London, England)|November 20, 2016
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyJosef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, et al.
Arthritis and Rheumatism|September 29, 2011
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugsRoy Fleischmann, Maurizio Cutolo, Mark C Genovese, et al.
The New England Journal of Medicine|June 19, 2014
Tofacitinib versus methotrexate in rheumatoid arthritisEun Bong Lee, Roy Fleischmann, Stephen Hall, et al.
RMD Open|June 24, 2026
Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Patrick Durez, et al.
Arthritis and Rheumatism|May 2, 2006
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trialPaul Emery, Roy Fleischmann, Anna Filipowicz-Sosnowska, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 4, 2014
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinibChristina Charles-Schoeman, Roy Fleischmann, Jean Davignon, et al.
RMD Open|March 23, 2017
Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitorsVibeke Strand, Matthew Reaney, Chieh-I Chen, et al.
Annals of Internal Medicine|September 13, 2013
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trialJoel Kremer, Zhan-Guo Li, Stephen Hall, et al.
Rheumatology (Oxford, England)|July 18, 2019
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-upRoy Fleischmann, Mark C Genovese, Yong Lin, et al.
Lancet (London, England)|June 21, 2017
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialRoy Fleischmann, Eduardo Mysler, Stephen Hall, et al.
Pageof 19

Showing results (151-160 of 190) with videos related to

Sort By:
Pageof 19
Lancet (London, England)|November 20, 2016
Head-to-head comparison of certolizumab pegol versus adalimumab in rheumatoid arthritis: 2-year efficacy and safety results from the randomised EXXELERATE studyJosef S Smolen, Gerd-Rüdiger Burmester, Bernard Combe, et al.
Arthritis and Rheumatism|September 29, 2011
Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugsRoy Fleischmann, Maurizio Cutolo, Mark C Genovese, et al.
The New England Journal of Medicine|June 19, 2014
Tofacitinib versus methotrexate in rheumatoid arthritisEun Bong Lee, Roy Fleischmann, Stephen Hall, et al.
RMD Open|June 24, 2026
Long-term safety and efficacy of upadacitinib compared with adalimumab in patients with rheumatoid arthritis: 7-year data from the SELECT-COMPARE studyRoy Fleischmann, Jerzy Swierkot, Patrick Durez, et al.
Arthritis and Rheumatism|May 2, 2006
The efficacy and safety of rituximab in patients with active rheumatoid arthritis despite methotrexate treatment: results of a phase IIB randomized, double-blind, placebo-controlled, dose-ranging trialPaul Emery, Roy Fleischmann, Anna Filipowicz-Sosnowska, et al.
Arthritis & Rheumatology (Hoboken, N.J.)|December 4, 2014
Potential mechanisms leading to the abnormal lipid profile in patients with rheumatoid arthritis versus healthy volunteers and reversal by tofacitinibChristina Charles-Schoeman, Roy Fleischmann, Jean Davignon, et al.
RMD Open|March 23, 2017
Sarilumab improves patient-reported outcomes in rheumatoid arthritis patients with inadequate response/intolerance to tumour necrosis factor inhibitorsVibeke Strand, Matthew Reaney, Chieh-I Chen, et al.
Annals of Internal Medicine|September 13, 2013
Tofacitinib in combination with nonbiologic disease-modifying antirheumatic drugs in patients with active rheumatoid arthritis: a randomized trialJoel Kremer, Zhan-Guo Li, Stephen Hall, et al.
Rheumatology (Oxford, England)|July 18, 2019
Long-term safety of sarilumab in rheumatoid arthritis: an integrated analysis with up to 7 years' follow-upRoy Fleischmann, Mark C Genovese, Yong Lin, et al.
Lancet (London, England)|June 21, 2017
Efficacy and safety of tofacitinib monotherapy, tofacitinib with methotrexate, and adalimumab with methotrexate in patients with rheumatoid arthritis (ORAL Strategy): a phase 3b/4, double-blind, head-to-head, randomised controlled trialRoy Fleischmann, Eduardo Mysler, Stephen Hall, et al.
Pageof 19